Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC. It operates through the following segments: Asia Pacific; Americas; and Europe, Middle East, and Africa. The company was founded in 1997 and is headquartered in North Sydney, Australia.